Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases
- PMID: 31596875
- PMCID: PMC6785117
- DOI: 10.1371/journal.pone.0223246
Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases
Abstract
Background: Previous studies of radiological damage in rheumatoid arthritis (RA) have used candidate-gene approaches, or evaluated single genome-wide association studies (GWAS). We undertook the first meta-analysis of GWAS of RA radiological damage to: (1) identify novel genetic loci for this trait; and (2) test previously validated variants.
Methods: Seven GWAS (2,775 RA cases, of a range of ancestries) were combined in a meta-analysis. Radiological damage was assessed using modified Larsen scores, Sharp van Der Heijde scores, and erosive status. Single nucleotide polymophsim (SNP) associations with radiological damage were tested at a single time-point using regression models. Primary analyses included age and disease duration as covariates. Secondary analyses also included rheumatoid factor (RF). Meta-analyses were undertaken in trans-ethnic and European-only cases.
Results: In the trans-ethnic primary meta-analysis, one SNP (rs112112734) in close proximity to HLA-DRB1, and strong linkage disequilibrium with the shared-epitope, attained genome-wide significance (P = 4.2x10-8). In the secondary analysis (adjusting for RF) the association was less significant (P = 1.7x10-6). In both trans-ethnic primary and secondary meta-analyses 14 regions contained SNPs with associations reaching P<5x10-6; in the European primary and secondary analyses 13 and 10 regions contained SNPs reaching P<5x10-6, respectively. Of the previously validated SNPs for radiological progression, only rs660895 (tagging HLA-DRB1*04:01) attained significance (P = 1.6x10-5) and had a consistent direction of effect across GWAS.
Conclusions: Our meta-analysis confirms the known association between the HLA-DRB1 shared epitope and RA radiological damage. The lack of replication of previously validated non-HLA markers highlights a requirement for further research to deliver clinically-useful prognostic genetic markers.
Conflict of interest statement
NAS has received less than $10,000 consultancies from Bristol myers squibb, and research grants from Mallinchrodt Pharmaceuticals and BWH (which is sponsored by Amgen, BMS, Sanofi/Regeneron, Dxterit, Crescendo and UCB). MEW has received less than $10,000 consultancies from Abbvie, Amgen, Novartis, Roche, Glaxo Smith Kline, Merck, Samsung, Crescendo Bioscience, Gilead, Pfizer and UCB, and over $10,000 from Lilly, and BMS. The BRASS study receives funding from Bristol myers squibb, Sanofi/Regeneron, AMGEN, and Crescendo Biosciences. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Figures
References
-
- Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum. 2002;31: 355–360. - PubMed
-
- Balsa A, Cabezon A, Orozco G, Cobo T, Miranda-Carus E, Lopez-Nevot MA, et al. Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor. Arthritis Res Ther. 2010;12: R62 10.1186/ar2975 - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
- U19 GM061388/GM/NIGMS NIH HHS/United States
- 36661 /VAC_/Versus Arthritis/United Kingdom
- MR/K006584/1/MRC_/Medical Research Council/United Kingdom
- 18387 /VAC_/Versus Arthritis/United Kingdom
- MR/M501633/2/MRC_/Medical Research Council/United Kingdom
- CRUK_/Cancer Research UK/United Kingdom
- G1001516/MRC_/Medical Research Council/United Kingdom
- BHF_/British Heart Foundation/United Kingdom
- MR/K015346/1/MRC_/Medical Research Council/United Kingdom
- RP-PG-0407-10314/DH_/Department of Health/United Kingdom
- 20011/VAC_/Versus Arthritis/United Kingdom
- 19739 /VAC_/Versus Arthritis/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- 18475 /VAC_/Versus Arthritis/United Kingdom
- CSO_/Chief Scientist Office/United Kingdom
- 05/40/04/DH_/Department of Health/United Kingdom
- MC_PC_13041/MRC_/Medical Research Council/United Kingdom
- G0902393/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Medical
Research Materials
